Oculus Innovative Sciences Announces New Regulatory Approvals and Target
Launch Dates for Three New Microcyn(R)-Based Products in Middle East Countries
PETALUMA, Calif., April 24, 2013 (GLOBE NEWSWIRE) -- Oculus Innovative
Sciences, Inc. (Nasdaq:OCLS) a global healthcare company that designs,
manufactures and markets prescription and non-prescription products in over 20
countries, today announced new regulatory approvals in Dubai, United Arab
Emirates, Kuwait, and Iraq for three new Microcyn®-based consumer products:
Face Cool™, a hydrogel for the treatment of acne and various dermatoses; Baby
Cool™, a hydrogel for treatment of baby rash; and Lady Cool™, a feminine
hygiene wash.All products are targeted to be launched in the fall of 2013.
Bruce Thornton, executive vice president of Oculus said: "We're excited to
broaden our product portfolio in these key Middle East countries to include
consumer products.The original Microcyn-based advanced wound management
offerings have garnered acclaim from healthcare institutions throughout the
region, many of which have reported a significant decline in healthcare costs
as a result of reductions in infections, reduced antibiotic use and days of
hospitalization.This cost-savings data was used in support of the regulatory
filings for these newest consumer products."
Dr. Walid Yousef, vice president of Joseph & Gionis, Oculus' master
distributor in the Middle East, added, "We are looking forward to the
commercialization of these new and unique products this coming fall through
our Dubai-based Microsafe Care Management subsidiary."
About Oculus Innovative Sciences
Oculus Innovative Science is a global healthcare company that designs,
manufactures and marketsprescription and non-prescription products in over 20
countries. The company's products are used to treat patients in
surgical/advanced wound management, dermatology, women's health and animal
health; addressing the unmet medical needs of these markets—while raising the
standard ofpatient care and lowering overall healthcare costs. The company's
headquarters are in Petaluma, California, with manufacturing operations in the
United States and Latin America. More information can be found
About Joseph and Gionis LLC
Joseph and Gionis, LLC is a premier consulting and biotechnology firm, which
specializes in mergers, acquisitions and excellence of service in fields,
which promote health, environment and welfare throughout the international
arena. The company's expertise in international law, international business,
cutting edge science and technology permits it to engage in a wide range of
portfolio experiences such as biotechnology, international capital trade, and
major project construction and oil and gas. Joseph and Gionis has offices in
Newport Beach, California and the United Arab Emirates. Please see the
company's web site at www.JosephandGionis.com.
Except for historical information herein,matters set forth in this press
release are forward-looking within the meaning of the "safe harbor" provisions
of the Private Securities Litigation Reform Act of 1995, including statements
about the Company's commercial and technology progress and futurefinancial
performance. These forward-looking statements are identified by the use of
words such as "target," "broaden" and"commercialization,"among others.
Forward-looking statements in this press release are subject to certain risks
and uncertainties inherent in the Company's business that could cause actual
results to vary, includingsuchrisks thatregulatory clinical and guideline
developments may change,scientific data may not be sufficient to meet
regulatory standards or receipt of required regulatory clearances or
approvals,clinical results may not be replicated in actual patient
settings,protection offered bythe Company'spatents and patent applications
may be challenged, invalidated or circumvented by its competitors,the
available market fortheCompany'sproducts will not be as large as
expected,the Company'sproducts will not be able to penetrate one or more
targeted markets,revenues will not be sufficient to fund further development
and clinical studies, the Company may not meet itsfuture capital needs, and
its ability to obtain additional funding, as well as uncertainties relative to
varying product formulations and a multitude of diverse regulatory and
marketing requirements in different countries and municipalities, and other
risks detailed from time to time in the Company's filings with the Securities
and Exchange Commission including the annual report on Form 10-K for theyear
ended March 31, 2012. Oculus Innovative Sciences disclaims any obligation to
update these forward-looking statements except as required by law.
Oculus and Microcyn Technology are trademarks or registered trademarks of
Oculus Innovative Sciences, Inc. All other trademarks and service marks are
the property of their respective owners.
CONTACT: Media and Investor Contact:
Oculus Innovative Sciences, Inc.
VP of Public and Investor Relations
Press spacebar to pause and continue. Press esc to stop.